Article Sidebar
Published:
Jan 17, 2025Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Lumefantrine-neusilin® based amorphous multicomponent solid dispersion: In vivo and in vitro characterization
Abstract
Purpose: To develop Neusilin-based amorphous multi-component solid dispersions (NAM-SDs) to improve poor aqueous solubility, low bioavailability and absorption of lumefantrine and enhance the antiplasmodial activity.
Methods: Solvent evaporation technique was adopted to produce second-generation SDs (N1 - N3); third-generation SDs (N4 - N6 and N10 - N12); and multi-component SDs, NAM-SDs, (N7 - N9 and N13 - N18). In vitro drug release, in vivo anti-plasmodial activity, differential scanning calorimetry (DSC), and wide-angle x-ray diffraction (WAXD) were carried out on the SDs.
Results: The highest drug release (80 %) was observed in multi-component SDs (NAM-SDs, formulation N17 containing Kollidon® VA 64). A significant antiplasmodial activity (p < 0.05) was observed in mice that received NAM-SDs. The DSC and WAXD studies showed that the formulations solubilized and exhibited an amorphous state.
Conclusion: Multi-component amorphous-based lumefantrine SDs (NAM-SDs) may serve as a potential alternative carrier system for oral lumefantrine delivery.
